2020 Fiscal Year Research-status Report
新規DNA相同組み換え機構に基づく細胞選択的合成致死誘導の開発
| Project/Area Number |
20K08071
|
|---|
| Research Institution | Yamagata University |
|---|
Principal Investigator |
田嶋 克史 山形大学, 医学部, 非常勤講師 (80292423)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
安田 武嗣 国立研究開発法人量子科学技術研究開発機構, 放射線医学総合研究所 放射線障害治療研究部, 主幹研究員(定常) (60332269)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | RAD52 / homologous recombination / acetylation / deacetylation |
|---|
| Outline of Annual Research Achievements |
We worked to find appropriate therapeutic target-enzymes of acetylation or deacetylation of RAd52 in BRCA1/2-dysfunctioned cells (Capan-1, BxPC3,and UWB1-cell line) and control cells. Several candidate enzymes were identified.
First, we examined whether the cell proliferation, viability, and sensitivity to anti-cancer agents of these cells were changed or not by the knock-down of the each candidate enzyme. Next, we have investigated the cell-proliferation and viability of cells with double-knock down of the candidate enzyme and BRCA1/2 by siRNA. We also investigated whether the double knockdown has impacts on he efficacy of homologous recombination induced by irradiation and anti-cancer agents.
|
| Current Status of Research Progress |
Current Status of Research Progress
3: Progress in research has been slightly delayed.
Reason
COVID-19の影響で、人流、研究機関移動が制限された。
|
| Strategy for Future Research Activity |
COVID-19による人流制限が解除または影響を受けない研究領域を先行して施行
|
| Causes of Carryover |
COVID-19の影響で研究活動が制限された
|
